That's simply incorrect. The company has stated that it is delaying the Brilacidin-ABSSSI clinical trial because of its high cost, and pursuing these much less expensive trials first.

Much less expensive means much less than 30 million dollars each. Therefore your claim that they will have to spend 30 million on each trial is wrong, pure and simple.

Likewise incorrect is your claim that they will have to dilute the stock by 30%, because of your incorrect claim that they need to raise 46 million for your incorrect claim of high-priced clinical trials. They don't need to raise 46 million, and if they did, they certainly would not do it all at once, at these low stock prices, with clinical trial news on several drugs due in the next few months. This is another incorrect claim that seems designed to scare prospective investors.

When someone appears with obviously incorrect scare tactics, then claims that they are just trying to "lay out what is needed for success," I call BS.